title: QTc prolongation and high-dose olanzapine.
authors.forename: Sean
authors.initials: S
authors.lastname: Dineen
authors.forename: Kirk
authors.initials: K
authors.lastname: Withrow
authors.forename: Liouda
authors.initials: L
authors.lastname: Voronovitch
authors.forename: Firoz
authors.initials: F
authors.lastname: Munshi
authors.forename: Mohammad Wally
authors.initials: MW
authors.lastname: Nawbary
authors.forename: Steven
authors.initials: S
authors.lastname: Lippmann
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced*; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects* / Q000031:analogs & derivatives*
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine